Comprehensive Cancer Centers Clinical Research
Comprehensive Cancer Centers of Nevada has a long-standing history of conducting clinical trials in Southern Nevada, bringing groundbreaking treatments close to home, including therapies not widely available elsewhere. For more than 20 years, Comprehensive has participated in over 120 Phase I, II, III, and IV clinical research studies annually. The organization has developed one of the largest Phase I clinical trial programs in Nevada, along with robust research programs in genitourinary cancers (prostate, kidney, and bladder) and gastrointestinal cancers. In addition, Comprehensive has extensive research efforts focused on breast, lung, head and neck, blood, and skin cancers.
Through these efforts, Comprehensive has contributed to the development of more than 100 FDA-approved cancer therapies.
Comprehensive Cancer Centers is now expanding its access to clinical trials and has partnered with Sarah Cannon Research Institute (SCRI), to bring more options to our patients. SCRI is one of the world’s leading oncology research organizations conducting community-based clinical trials at more than 200 locations in more than 20 states across the U.S. Focused on advancing therapies for patients for more than three decades, SCRI is a leader in drug development.
Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting clinical trials in the community. SCRI has contributed to pivotal research that has led to the majority of new cancer therapies approved by the U.S. Food and Drug Administration (FDA) in the past decade.